Skip to content

A Randomized Controlled Study on Autologous Platelet-rich Plasma Injection in Patients with Poor Ovarian Response

A Randomized Controlled Study on Autologous Platelet-rich Plasma Injection in Patients with Poor Ovarian Response

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114186
Enrollment
Unknown
Registered
2025-12-09
Start date
2025-12-15
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor ovarian response

Interventions

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Women with fertility requirements who are attending the Centre for Reproductive Medicine of the Third North Medical College for IVF treatment 2. Age =1 year 3. Fulfilling the diagnostic criteria of POI or the diagnostic criteria of POR Posidon 4. Previously, the number of eggs obtained by controlled ovulation was =2 times 5. The uterus and the adnexa on both sides were sound 6. BMI 18.5-29kg /? 7. Subjects must give informed consent to the study and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Congenital abnormalities of reproductive organs 2. Septicemia, platelet dysfunction syndrome and severe thrombocytopenia and other coagulation disorders or other hematological diseases 3. Suffering from autoimmune diseases or other endocrine diseases, with abnormal thyroid function and uncontrolled condition 4. Having a mass in the adnexal area with an unclear benign or malignant nature 5. Complicated with severe cardiovascular and cerebrovascular diseases, malignant tumors, hematological diseases and mental disorders, patients with impaired function of important organs 6. Those who have used systemic corticosteroids within the last 2 weeks, or used antiplatelet drugs such as aspirin within the last 48 hours 7. In the acute inflammatory stage 8. Those with a history of venous thrombosis or pulmonary embolism during the screening period

Design outcomes

Primary

MeasureTime frame
Number of retrieved oocytes;

Secondary

MeasureTime frame
Blood anti-Müllerian hormone (AMH) level;Number of antral follicles (AFC);clinical pregnancy rate;

Countries

Chian

Contacts

Public ContactCaihong Ma

Peking University Third Hospital

macaihong@bjmu.edu.cn+86 10 8226 6699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026